Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02GEC
|
|||
| Former ID |
DAP000387
|
|||
| Drug Name |
Omalizumab
|
|||
| Synonyms |
Xolair; Omalizumab (genetical recombination); Xolair (TN); Omalizumab (USAN/INN); Omalizumab (genetical recombination) (JAN)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Approved | [1], [2], [3], [4] | |
| Chronic idiopathic urticaria [ICD-11: EB00.1; ICD-10: L50.1; ICD-9: 708] | Phase 2 | [1], [2] | ||
| Therapeutic Class |
Antiasthmatic Agents
|
|||
| Company |
National University Hospital, Singapore|National University, Singapore
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01610 | |||
| SuperDrug ATC ID |
R03DX05
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin epsilon Fc receptor gamma (FCERG) | Target Info | Modulator | [5] |
| KEGG Pathway | Sphingolipid signaling pathway | |||
| Fc epsilon RI signaling pathway | ||||
| Asthma | ||||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Reactome | Fc epsilon receptor (FCERI) signaling | |||
| Role of LAT2/NTAL/LAB on calcium mobilization | ||||
| FCERI mediated MAPK activation | ||||
| FCERI mediated Ca+2 mobilization | ||||
| FCERI mediated NF-kB activation | ||||
| WikiPathways | IL1 and megakaryotyces in obesity | |||
| Fc epsilon receptor (FCERI) signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6890). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | ClinicalTrials.gov (NCT00546143) Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma | |||
| REF 4 | ClinicalTrials.gov (NCT01701583) Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria | |||
| REF 5 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.